Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Interest Rates
Economy
Global Metrics

Taysha Gene Therapies Change in Accounts Receivable 2020-2024 | TSHA

Taysha Gene Therapies change in accounts receivable from 2020 to 2024. Change in accounts receivable can be defined as the increase or decrease in accounts receivable for the given period.
  
Taysha Gene Therapies Annual Change in Accounts Receivable
(Millions of US $)
2024 $N/A
2023 $N/A
2022 $N/A
2021 $N/A
2020 $N/A
2019 $N/A
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.338B $0.015B
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.010B 6.96
Dr Reddy's Laboratories (RDY) India $11.261B 21.48
BridgeBio Pharma (BBIO) United States $6.894B 0.00
Bausch Health Cos (BHC) Canada $2.638B 1.91
Supernus Pharmaceuticals (SUPN) United States $1.805B 24.57
Amphastar Pharmaceuticals (AMPH) United States $1.553B 9.33
Personalis (PSNL) United States $0.323B 0.00
Assembly Biosciences (ASMB) United States $0.080B 0.00
Sol-Gel Technologies (SLGL) Israel $0.016B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00